Should I buy or sell Vor Biopharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VOR shares. View VOR analyst ratings or view top-rated stocks .

What is Vor Biopharma's stock price target for 2024?

5 Wall Street research analysts have issued 1-year target prices for Vor Biopharma's shares. Their VOR share price targets range from $11.00 to $17.50. On average, they anticipate the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 689.5% from the stock's current price. View analysts price targets for VOR or view top-rated stocks among Wall Street analysts .

How have VOR shares performed in 2024?

Vor Biopharma's stock was trading at $2.25 at the beginning of the year. Since then, VOR stock has decreased by 24.0% and is now trading at $1.71. View the best growth stocks for 2024 here .

When is Vor Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VOR earnings forecast .

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NYSE:VOR) posted its earnings results on Wednesday, March, 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.10.

What ETFs hold Vor Biopharma's stock?

ETFs with the largest weight of Vor Biopharma (NYSE:VOR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Loncar China Biopharma ETF (CHNA) .

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:VOR

Vor Biopharma (VOR) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free VOR Stock Alerts

$1.71

+0.03 (+1.79%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.66
▼
$1.74
50-Day Range: $1.68
▼
$2.37
52-Week Range: $1.62
▼
$5.70

Volume: 199,054 shs
Average Volume: 317,194 shs
Market Capitalization: $116.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.50

Get Vor Biopharma alerts:

Vor Biopharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 689.5% Upside
$13.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.34) to ($1.31) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

345th out of 911 stocks

4.5

Analyst's Opinion

Consensus Rating
Vor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vor Biopharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for VOR.

0.0

Dividend Strength

Dividend Yield
Vor Biopharma does not currently pay a dividend.
Dividend Growth
Vor Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VOR.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Vor Biopharma this week, compared to 1 article on an average week.
Search Interest
Only 10 people have searched for VOR on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vor Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.40% of the stock of Vor Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Vor Biopharma are expected to grow in the coming year, from ($1.34) to ($1.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vor Biopharma is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vor Biopharma is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Vor Biopharma Stock (NYSE:VOR)

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VOR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VOR Stock News Headlines

April 16, 2024 | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Trading Down 5.3%

April 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 1, 2024 | globenewswire.com

Vor Bio to Participate in Upcoming Investor Conferences

March 29, 2024 | finance.yahoo.com

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

March 28, 2024 | investorplace.com

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

March 26, 2024 | markets.businessinsider.com

Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)

March 22, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 22, 2024 | finanznachrichten.de

Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 21, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)

March 20, 2024 | benzinga.com

Vor Biopharma: Q4 Earnings Insights

March 20, 2024 | finance.yahoo.com

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 20, 2024 | globenewswire.com

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

March 19, 2024 | msn.com

Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trial

March 16, 2024 | finance.yahoo.com

VOR Apr 2024 5.000 call

March 5, 2024 | globenewswire.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 4, 2024 | globenewswire.com

Vor Bio to Participate in Upcoming Investor Conferences

February 17, 2024 | finance.yahoo.com

Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company

February 15, 2024 | finance.yahoo.com

2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)

February 7, 2024 | finance.yahoo.com

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024 | finanznachrichten.de

Personnel changes in the Exyte management: Mark Garvey and Elena Bashkeeva are welcomed as new members of the Executive Board

January 31, 2024 | msn.com

Vaxart spikes as B. Riley upgrades at long last after BARDA funding

January 18, 2024 | finanznachrichten.de

Vor Biopharma: Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

January 17, 2024 | finance.yahoo.com

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

January 9, 2024 | markets.businessinsider.com

Buy Rating Justified by CRISPR Therapeutics’ Strong Pipeline and Market Potential

November 9, 2023 | finance.yahoo.com

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

See More Headlines

Receive VOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/20/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: N/A
Sub-Industry: N/A
Current Symbol: NYSE:VOR
CUSIP: N/A
CIK: 1817229
Web: www.vorbiopharma.com
Phone: 617-655-6580
Fax: N/A
Employees: 168
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.50
High Stock Price Target: $17.50
Low Stock Price Target: $11.00
Potential Upside/Downside: +689.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 68,220,000
Free Float: 59,757,000
Market Cap: $116.66 million
Optionable: Not Optionable
Beta: -0.36

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Robert Ang M.B.A. (Age 49)
M.D., MBBS, President, CEO & Director
Comp: $943.91k
Mr. Samir Vattompadam M.S.
Senior Vice President of Portfolio Strategy & Program Management
Mr. David Phillips M.B.A.
Senior VP & Head of Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VOR Stock Analysis - Frequently Asked Questions

Should I buy or sell Vor Biopharma stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VOR shares.
View VOR analyst ratings or view top-rated stocks.
What is Vor Biopharma's stock price target for 2024?: 5 Wall Street research analysts have issued 1-year target prices for Vor Biopharma's shares. Their VOR share price targets range from $11.00 to $17.50. On average, they anticipate the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 689.5% from the stock's current price.
View analysts price targets for VOR or view top-rated stocks among Wall Street analysts.
How have VOR shares performed in 2024?: Vor Biopharma's stock was trading at $2.25 at the beginning of the year. Since then, VOR stock has decreased by 24.0% and is now trading at $1.71.
View the best growth stocks for 2024 here.
When is Vor Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VOR earnings forecast.

How were Vor Biopharma's earnings last quarter?: Vor Biopharma Inc. (NYSE:VOR) posted its earnings results on Wednesday, March, 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.10.
What ETFs hold Vor Biopharma's stock?: ETFs with the largest weight of Vor Biopharma (NYSE:VOR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).
When did Vor Biopharma IPO?: Vor Biopharma (VOR) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO.
How do I buy shares of Vor Biopharma?: Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:VOR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vor Biopharma (VOR) Stock Price, News & Analysis

Vor Biopharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vor Biopharma Stock (NYSE:VOR)

VOR Stock Price History

VOR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

VOR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™